How healthcare’s small- and mid-cap companies could benefit from one of today’s key macroeconomic growth drivers: aging populations.
Insights
Our latest thinking on the themes shaping today’s investment landscape. Explore timely updates, quarterly features and in-depth analysis straight from our experts.
With populations in some of the largest economies quickly graying, innovative small- and mid-cap healthcare companies could deliver new growth opportunities for investors.
Several factors are coming together that could help push the biotech sector higher.
With depressed valuations and accelerating innovation, we believe the sector offers an attractive combination for long-term investors.
Agustin Mohedas discusses the market opportunity associated with GLP-1 agonists, the new drug tackling obesity.
Andy Acker and Dan Lyons share their outlook, saying a rapid pace of innovation and attractive valuations could propel the sector higher.
These healthcare subsectors offer an attractive combination of long-term growth drivers at below-average valuations.
Attractive valuations and innovation are adding to the sector’s long-term appeal.
How innovation, secular tailwinds – even regulation – are driving growth in the sector.
New weight-loss medications could dramatically improve patient health – with big implications for the healthcare sector.
The biopharmaceutical industry often moves to the beat of its own drum, creating opportunities for diversification.